Top

Published in:

01-05-2018 | Editorial

The growing burden of liver cirrhosis: implications for preventive measures

Authors: Martin C. S. Wong, Junjie Huang

Published in: Hepatology International | Issue 3/2018

Excerpt

Liver cirrhosis has become one of the major causes of morbidity and mortality. The Global Burden of Disease (GBD) reported that over one million people died due to cirrhosis in 2010 worldwide, compared with 676,000 deaths in 1980. Since the survival rate of cirrhosis is relatively low, data on the incidence of geographical variations are essential to prevent its related disability and mortality. However, the heavy burden of this medical condition might be even greater, as relevant data in 58/187 (31%) of countries were not available in the report [1]. …

Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, Murray C, Naghavi M. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014. https://doi.org/10.1186/s12916-014-0145-y.PubMedPubMedCentralCrossRef

Byass P. The global burden of liver disease: a challenge for methods and for public health. BMC Med. 2014. https://doi.org/10.1186/s12916-014-0159-5.CrossRefPubMedPubMedCentral

Wong MC, Huang JL, George J, Huang J, Leung C, Eslam M, Chan HLY, Ng SC. The changing epidemiology of liver diseases in Asia-Pacific. Nat Rev Gastroenterol Hepatol. 2018 (accepted).

Rehm J, Taylor B, Mohapatra S, Irving H, Baliunas D, Patra J, Roerecke M. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev. 2010;29(4):437–45. https://doi.org/10.1111/j.1465-3362.2009.00153.x.CrossRefPubMed

Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: evidence based treatment. World J Gastroenterol. 2014;20(18):5442. https://doi.org/10.3748/wjg.v20.i18.5442.CrossRefPubMedPubMedCentral

Wong MC, Jiang JY, Goggins WB, Liang M, Fang Y, Fung FD, Leung C, Wang HH, Wong GL, Wong VW, Chan HL. International incidence and mortality trends of liver cancer: a global profile. Sci Rep. 2017;31(7):45846. https://doi.org/10.1038/srep45846.CrossRef

Wong MC, Ching JY, Chan VC, Lam TY, Luk AK, Wong SH, Ng SC, Wong VW, Ng SS, Wu JC, Chan FK, Sung JJ. Screening strategies for colorectal cancer among patients with nonalcoholic fatty liver disease and family history. Int J Cancer. 2016;138(3):576–83. https://doi.org/10.1002/ijc.29809 Epub 2015 Sep 1.CrossRefPubMed

Schuppan D, Afdhal NH. Liver cirrhosis. The Lancet. 2018;371(9615):838–51. https://doi.org/10.1016/s0140-6736(08)60383-9.CrossRef

Chung W, Jo C, Chung WJ, Kim DJ. Liver cirrhosis and cancer: comparison of mortality. Hepatol Int. 2018. https://doi.org/10.1007/s12072-018-9850-5.PubMedCrossRef

10.

Williams R, Alexander G, Armstrong I, Baker A, Bhala N, Camps-Walsh G, Cramp ME, de Lusignan S, Day N, Dhawan A, Dillon J, Drummond C, Dyson J, Foster G, Gilmore I, Hudson M, Kelly D, Langford A, McDougall N, Meier P, Moriarty K, Newsome P, O’Grady J, Pryke R, Rolfe L, Rice P, Rutter H, Sheron N, Taylor A, Thompson J, Thorburn D, Verne J, Wass J, Yeoman A. Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK. Lancet. 2018. 391(10125):1097–107.CrossRefPubMed

11.

Williams R, Alexander G, Aspinall R, Bosanquet J, Camps-Walsh G, Cramp M, Day N, Dhawan A, Dillon J, Dyson J, Ferguson J, Foster G, Gardner R, Gilmore SI, Hardman L, Hudson M, Kelly D, Langford A, Liversedge S, Moriarty K, Newsome P, O’Grady J, Pryke R, Rolfe L, Rutter H, Ryder S, Samyn M, Sheron N, Taylor A, Thompson J, Verne J, Yeoman A. New metrics for the Lancet Standing Commission on Liver Disease in the UK. Lancet. 2017;389(10083):2053–80.CrossRefPubMed

12.

Williams R, Ashton K, Aspinall R, Bellis MA, Bosanquet J, Cramp ME, Day N, Dhawan A, Dillon J, Dyson J, Ferguson J, Foster G, Gilmore SI, Glynn M, Guthrie JA, Hudson M, Kelly D, Langford A, Newsome P, O’Grady J, Pryke R, Ryder S, Samyn M, Sheron N, Verne J. Implementation of the Lancet Standing Commission on Liver Disease in the UK. Lancet. 2015;386(10008):2098–111.CrossRefPubMed

13.

Williams R, Aspinall R, Bellis M, Camps-Walsh G, Cramp M, Dhawan A, Ferguson J, Forton D, Foster G, Gilmore I, Hickman M, Hudson M, Kelly D, Langford A, Lombard M, Longworth L, Martin N, Moriarty K, Newsome P, O’Grady J, Pryke R, Rutter H, Ryder S, Sheron N, Smith T. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet. 2014;384(9958):1953–97.CrossRefPubMed

Title: The growing burden of liver cirrhosis: implications for preventive measures
Authors: Martin C. S. Wong
Junjie Huang
Publication date: 01-05-2018
Publisher: Springer India
Published in: Hepatology International / Issue 3/2018
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-018-9865-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The growing burden of liver cirrhosis: implications for preventive measures

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2018

Correction to: Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B

Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan

Correction to: Abstracts of the 27th Annual Conference of APASL, March 14–18, 2018, New Delhi, India

Immune checkpoint receptors: homeostatic regulators of immunity

Beyond KCH selection and options in acute liver failure

Platelets’ increase is associated with improvement of liver fibrosis in entecavir-treated chronic hepatitis B patients with significant liver fibrosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page